Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Monday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ ADXS opened at $0.03 on Monday. The stock has a fifty day moving average price of $0.03 and a two-hundred day moving average price of $0.04. The firm has a market cap of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.78.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.